Nanobiotechnology-based delivery strategies: New frontiers in brain tumor targeted therapies

Mangraviti, Antonella; Gullotti, David; Tyler, Betty; Brem, Henry

doi:10.1016/j.jconrel.2016.03.031

Cited by 51 publications

(17 citation statements)

References 191 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the studies about BBB have significant meaning to neurological diseases. The discovery of capability of Butylphalide and its metabolites in mild passing through BBB not only lighten the way for improvement of outcome of ischemic cerebrovascular diseases and MS, but also give us hope for find cures for other deadly CNS disorders like degenerative diseases and tumor by combining with nanotechnology [18].…”

Section: Potential Application Of Butylphthalide In Treatment Of Multmentioning

confidence: 99%

A Brief Discussion of Mechanism of Butylphthalide in Treatment of Ischemic Cerebrovascular Disease and its Potential Clinical Applicationin Treatment of Multiple Sclerosis

Wang¹,

Zhang²,

Tan³

2016

JCCR

View full text Add to dashboard Cite

A Chinese traditional medicine Butylphthalide (NBP) has been proved effects in ischemic cerebrovascular disease. Here we discuss the mechanism of NBP in treatment of ischemic stroke, and find its capability in penetrating and modulating Blood-brain barrier (BBB), reducing harmful inflammation and formation of scars in injury CNS tissue, which implicate the potential application of NBP in treatment of Multiple Sclerosis (MS).

show abstract

Section: Potential Application Of Butylphthalide In Treatment Of Multmentioning

confidence: 99%

A Brief Discussion of Mechanism of Butylphthalide in Treatment of Ischemic Cerebrovascular Disease and its Potential Clinical Applicationin Treatment of Multiple Sclerosis

Wang¹,

Zhang²,

Tan³

2016

JCCR

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

“…Nowadays, brain tumors inside the complex central nervous system remain one of the most challenging cancers to diagnose . This urges the emergence of novel brain‐imaging modalities and the corresponding contrast agents, which work together to offer outcomes with good sensitivity and specificity, deep penetration, high spatial and temporal resolution . Conventional brain‐imaging techniques like positron emission tomography (PET), computed tomography (CT), ultrasound imaging (US), single‐photon emission computed tomography (SPET), and magnetic resonance imaging (MRI) have unlimited penetration, but show certain drawbacks, such as being hazardous to both patients and operators with the ionization energy source (for CT, PET, and SPECT), poor‐soft tissue contrast (for CT), limited spatial resolution (for US, MRI, and PET), and long acquisition time (for MRI and CT) .…”

mentioning

confidence: 99%

“…Owing to the hydrophobic nature of organic fluorophores, usually they are loaded into polymer matrices to realize water dispersibility, biostability in vivo, tumor targeting capability, and the ultimate imaging efficacy . Nevertheless, most conventional fluorophores show weakened or annihilated fluorescence inside NPs as a result of aggregation‐caused quenching (ACQ) .…”

mentioning

confidence: 99%

See 1 more Smart Citation

Bright Aggregation‐Induced‐Emission Dots for Targeted Synergetic NIR‐II Fluorescence and NIR‐I Photoacoustic Imaging of Orthotopic Brain Tumors

et al. 2018

View full text Add to dashboard Cite

Precise diagnostics are of significant importance to the optimal treatment outcomes of patients bearing brain tumors. NIR-II fluorescence imaging holds great promise for brain-tumor diagnostics with deep penetration and high sensitivity. This requires the development of organic NIR-II fluorescent agents with high quantum yield (QY), which is difficult to achieve. Herein, the design and synthesis of a new NIR-II fluorescent molecule with aggregation-induced-emission (AIE) characteristics is reported for orthotopic brain-tumor imaging. Encapsulation of the molecule in a polymer matrix yields AIE dots showing a very high QY of 6.2% with a large absorptivity of 10.2 L g cm at 740 nm and an emission maximum near 1000 nm. Further decoration of the AIE dots with c-RGD yields targeted AIE dots, which afford specific and selective tumor uptake, with a high signal/background ratio of 4.4 and resolution up to 38 µm. The large NIR absorptivity of the AIE dots facilitates NIR-I photoacoustic imaging with intrinsically deeper penetration than NIR-II fluorescence imaging and, more importantly, precise tumor-depth detection through intact scalp and skull. This research demonstrates the promise of NIR-II AIE molecules and their dots in dual NIR-II fluorescence and NIR-I photoacoustic imaging for precise brain cancer diagnostics.

show abstract

“…However, a specific post-surgical solution was the clinically successful implantable wafer, Gliadel ™ , which is placed into the tumor-resected cavity. It is the only FDA-approved intracranial drug delivery system available in the clinic for the last two decades2627282930. Pioneering work done by Henry Brem and Robert Langer et al ., lead to the development of this pelletized microparticle implant, formed by a surface-eroding polyanhydride, p -Carboxyphenoxy propane-sebacic acid (CPP-SA), which delivers oncolytic agent, Carmustine (BCNU), for nearly 7 days (90%).…”

mentioning

confidence: 99%

Theranostic 3-Dimensional nano brain-implant for prolonged and localized treatment of recurrent glioma

Ramachandran

Junnuthula

Gowd

et al. 2017

Sci Rep

108

View full text Add to dashboard Cite

Localized and controlled delivery of chemotherapeutics directly in brain-tumor for prolonged periods may radically improve the prognosis of recurrent glioblastoma. Here, we report a unique method of nanofiber by fiber controlled delivery of anti-cancer drug, Temozolomide, in orthotopic brain-tumor for one month using flexible polymeric nano-implant. A library of drug loaded (20 wt%) electrospun nanofiber of PLGA-PLA-PCL blends with distinct in vivo brain-release kinetics (hours to months) were numerically selected and a single nano-implant was formed by co-electrospinning of nano-fiber such that different set of fibres releases the drug for a specific periods from days to months by fiber-by-fiber switching. Orthotopic rat glioma implanted wafers showed constant drug release (116.6 μg/day) with negligible leakage into the peripheral blood (<100 ng) rendering ~1000 fold differential drug dosage in tumor versus peripheral blood. Most importantly, implant with one month release profile resulted in long-term (>4 month) survival of 85.7% animals whereas 07 day releasing implant showed tumor recurrence in 54.6% animals, rendering a median survival of only 74 days. In effect, we show that highly controlled drug delivery is possible for prolonged periods in orthotopic brain-tumor using combinatorial nanofibre libraries of bulk-eroding polymers, thereby controlling glioma recurrence.

show abstract

Nanobiotechnology-based delivery strategies: New frontiers in brain tumor targeted therapies

Cited by 51 publications

References 191 publications

A Brief Discussion of Mechanism of Butylphthalide in Treatment of Ischemic Cerebrovascular Disease and its Potential Clinical Applicationin Treatment of Multiple Sclerosis

A Brief Discussion of Mechanism of Butylphthalide in Treatment of Ischemic Cerebrovascular Disease and its Potential Clinical Applicationin Treatment of Multiple Sclerosis

Bright Aggregation‐Induced‐Emission Dots for Targeted Synergetic NIR‐II Fluorescence and NIR‐I Photoacoustic Imaging of Orthotopic Brain Tumors

Theranostic 3-Dimensional nano brain-implant for prolonged and localized treatment of recurrent glioma

Contact Info

Product

Resources

About